Abstracts tagged "Janus kinase (JAK)"

Abstract Number: 507 • 2019 ACR/ARP Annual Meeting
Inhibition of Joint Destruction in Patients with Rheumatoid Arthritis Treated with Peficitinib in Combination with Methotrexate: A Randomized, Double-Blind, Placebo-Controlled Trial in Japan
Tsutomu Takeuchi¹, Yoshiya Tanaka ², Mitsuhiro Rokuda ³, Hiroyuki Izutsu ³, Yuichiro Kaneko ³, Musashi Fukuda ³, Daisuke Kato ³ and Désirée van der Heijde ⁴, ¹Keio University School of Medicine, Tokyo, Japan, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Astellas Pharma, Inc., Tokyo, Japan, ⁴Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Peficitinib (PEF), a novel oral Janus kinase (JAK) inhibitor, has demonstrated efficacy in Phase 3 studies of patients with RA (NCT02305849).1 We report the…
Abstract Number: 2907 • 2019 ACR/ARP Annual Meeting
Clinical and Functional Outcomes Among Rheumatoid Arthritis Patients Switching Between JAK1-Selective Inhibitor Upadacitinib and Adalimumab Following Insufficient Response
Roy Fleischmann¹, Mark Genovese ², Ricardo Blanco ³, Stephen Hall ⁴, Glen Thomson ⁵, Filip Van den Bosch ⁶, Cristiano A. Zerbini ⁷, Jose Jeffrey Enejosa ⁸, Yihan Li ⁹, Ryan DeMasi ⁹ and In-Ho Song ⁸, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Stanford University, Stanford, CA, ³Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, ⁴Monash University and Emeritus Research, Melbourne, Australia, ⁵CIADS Research, Winnipeg, Canada, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Centro Paulista de Investigação Clinica, São Paulo, Brazil, ⁸AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁹AbbVie Inc., North Chicago, IL
Background/Purpose: The goal of RA treatment is to achieve clinical remission or, at minimum, low disease activity (LDA). Modification of initial csDMARD therapy with the…
Abstract Number: 992 • 2019 ACR/ARP Annual Meeting
Identification of CJ-15314, a Novel Highly Selective JAK1 Inhibitor, for the Treatment of Rheumatoid Arthritis
So Young Ki¹, Dongkyu Kim ¹, Juhyun Lee ¹, Byoung Seok Moon ¹ and Shin-Young Ryu ¹, ¹CJ Healthcare, Icheon-si, Republic of Korea
Background/Purpose: Janus kinases (JAKs) play critical roles in mediating various cytokine signaling. First-generation non-selective JAK inhibitors such as tofacitinib and baricitinib are widely used for…
Abstract Number: 1352 • 2019 ACR/ARP Annual Meeting
Effects of Upadacitinib on Patient-Reported Outcomes After 24 Weeks in Patients with Active Rheumatoid Arthritis and an Inadequate Response to Conventional Synthetic or Biologic Disease-Modifying Anti-Rheumatic Drugs: Results from SELECT-NEXT and SELECT-BEYOND Phase 3 Studies
Martin Bergman¹, Namita Tundia ², Heidi Camp ², Sebastian Meerwein ³, Casey Schlacher ², Debbie Goldschmidt ⁴, Yan Song ⁵ and Vibeke Strand ⁶, ¹Drexel University College of Medicine, Stockholm, Sweden, ²AbbVie Inc., North Chicago, IL, ³AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, ⁴Analysis Group, Inc., New York, NY, ⁵Analysis Group, Inc., Boston, MA, ⁶Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Treatment with upadacitinib (UPA), a selective Janus kinase-1 (JAK-1) inhibitor, resulted in significant and clinically meaningful improvements in patient-reported outcomes (PROs) at Week 12…
Abstract Number: 1375 • 2019 ACR/ARP Annual Meeting
Patient-Reported Outcomes of Upadacitinib versus Adalimumab Use in Patients with Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate: 26-Week Analysis of a Phase 3 Study
Roy Fleischmann¹, Martin Bergman ², Namita Tundia ³, In-Ho Song ⁴, Jessica Suboticki ⁴, Yan Song ⁵ and Vibeke Strand ⁶, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Drexel University College of Medicine, Stockholm, Sweden, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁵Analysis Group, Inc., Boston, MA, ⁶Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: In patients with active rheumatoid arthritis (RA), 12-week treatment with upadacitinib (UPA) while on background MTX therapy resulted in significant and clinically meaningful improvements…
Abstract Number: 1376 • 2019 ACR/ARP Annual Meeting
Impact of 24- or 26-Week Upadacitinib Monotherapy on Patient-Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis and No Prior Use of or an Inadequate Response to Methotrexate: Results from Two Phase 3 Trials
Vibeke Strand¹, Namita Tundia ², Alan Friedman ³, Heidi Camp ², Jessica Suboticki ⁴, Debbie Goldschmidt ⁵, Catherine Fernan ⁵ and Martin Bergman ⁶, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²AbbVie Inc., North Chicago, IL, ³AbbVie Inc., North Chicago, ⁴AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁵Analysis Group, Inc., New York, NY, ⁶Drexel University College of Medicine, Stockholm, Sweden
Background/Purpose: Treatment with upadacitinib (UPA) monotherapy, a selective Janus kinase-1 (JAK-1) inhibitor, resulted in significant and clinically meaningful improvements in patient-reported outcomes (PROs) at Week…
Abstract Number: 1400 • 2019 ACR/ARP Annual Meeting
Real Life Retention of Tofacitinib in Patients with Rheumatoid Arthritis
Aniela Croiteru ¹, Merav Lidar ², Tatiana Reitblat³, Devy Zisman ⁴, Alexandra Balbir-Gurman ⁵, Tanya Meshiach ⁵, Ronit Almog ⁵ and Ori Elkayam ⁶, ¹Tel Aviv medical center, Tel Aviv, Israel, ²Sheba Medical Center, Ramat Gan, Israel, ³Barzilai Medical Center, Ashkelon, Israel, ⁴Carmel Hospital and Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel, Haifa, Israel, ⁵Rambam Medical Center, Haifa, Israel, ⁶Rheumatology Department, Tel Aviv Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Israel., Tel Aviv, Israel
Background/Purpose: Tofacitinib (Xeljanz) is an approved treatment for Rheumatoid Arthritis (RA) but data on its use in “real life” are limited. We sought to analyze…
Abstract Number: L06 • 2018 ACR/ARHP Annual Meeting
Safety and Efficacy of Filgotinib in a Phase 3 Trial of Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic Dmards
Mark C. Genovese¹, Kenneth C. Kalunian², David Walker³, Jacques-Eric Gottenberg⁴, Kurt de Vlam⁵, Neelufar Mozaffarian⁶, Beatrix Bartok⁶, Franziska Matzkies⁶, Jie Gao⁶, Ying Guo⁶, Chantal Tasset⁷, John S. Sundy⁶ and Tsutomu Takeuchi⁸, ¹Division of Immunology & Rheumatology, Stanford University, Stanford, CA, ²Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, ³Northumbria Healthcare, United Kingdom, United Kingdom, ⁴Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁵Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, ⁶Gilead Sciences, Inc., Foster City, CA, ⁷Galapagos NV, Mechelen, Belgium, Mechelen, Belgium, ⁸Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor was effective in phase 2 studies of active RA in patients (pts) with insufficient…
Abstract Number: 1401 • 2018 ACR/ARHP Annual Meeting
Is There a Specific Effect of Jak-Inhibitors on Pain and Fatigue in Rheumatoid Arthritis?
Itsaso Odriozola¹, Claire-Sophie Coste¹, Thomas Barnetche^2,3, Christophe Richez^4,5, Bernard Bannwarth¹ and Thierry Schaeverbeke⁶, ¹Rheumatology, CHU de Bordeaux, Bordeaux, France, ²FHU ACRONIM, Pellegrin Hospital, Bordeaux University, Bordeaux, France, ³Rheumatology, Centre hospitalier universitaire de Bordeaux - Service de Rhumatologie, Bordeaux, France, ⁴UMR CNRS 5164 - Immunoconcept, Bordeaux, France, ⁵Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France, ⁶Department of Rheumatology, Bordeaux University Hospital, BORDEAUX, France
Background/Purpose: Pain and fatigue are common symptoms for patients with rheumatoid arthritis (RA).JAK inhibitors (JAKi) already proved similar efficacy on disease activity as bDMARD (anti-TNF,…
Abstract Number: 2546 • 2018 ACR/ARHP Annual Meeting
The Association between Patient Reported Outcomes and Clinical Measures Among Rheumatoid Arthritis Patients: Analyses Using Phase 3 Clinical Trials of Upadacitinib
Vibeke Strand¹, Nemanja Damjanov², Craig Scoville³, Namita Tundia⁴, Heidi S. Camp⁴, Kun Chen⁴, Jessica Suboticki⁴ and Ronald van Vollenhoven⁵, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²Institute of Rheumatology, Belgrade University School of Medicine, Belgrade, Serbia, ³Idaho Falls Arthritis Clinic, Idaho Falls, ID, ⁴AbbVie Inc., North Chicago, IL, ⁵Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands
Background/Purpose: Patient-reported outcomes (PROs) in RA are important to evaluate total disease impact, although treatment decisions may often be guided by traditional physician-derived measures of…
Abstract Number: 1518 • 2018 ACR/ARHP Annual Meeting
Baricitinib and Tofacitinib in Real Life – Does Obesity Impact Response to Janus Kinase Inhibitor Therapy in Rheumatoid Arthritis?
Yvette Meißner¹, Lisa Baganz¹, Matthias Schneider², Ilka Schwarze³, Martin Feuchtenberger⁴, Angela Zink⁵ and Anja Strangfeld⁶, ¹Programme Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Department of Rheumatology & Hiller Research Unit, Medical Faculty, University Hospital, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ³Praxis internistische Rheumatologie, Leipzig, Germany, ⁴Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, ⁵Epidemiology Unit / Rheumatology and Clinical Immunology, German Rheumatism Research Centre (DRFZ) / Charité University Hospital, Berlin, Germany, ⁶Epidemiology, German Rheumatism Research Center, Berlin, Germany
Background/Purpose: The influence of obesity on treatment response of tumor necrosis factor inhibitors in patients with rheumatoid arthritis (RA) is described in literature, but data…
Abstract Number: 2547 • 2018 ACR/ARHP Annual Meeting
Upadacitinib Monotherapy Improves Patient-Reported Outcomes in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate
Vibeke Strand¹, Maya Buch², Namita Tundia³, Heidi S. Camp³, Jessica Suboticki³, Debbie Goldschmidt⁴ and Alvin F. Wells⁵, ¹Stanford University, Palo Alto, CA, ²NIHR Leeds Musculoskeletal Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³AbbVie Inc., North Chicago, IL, ⁴Analysis Group Inc., New York, NY, ⁵Rheumatology and Immunotherapy Center, Franklin, WI
Background/Purpose: Upadacitinib (UPA) is a selective JAK-1 inhibitor with demonstrated patient-reported benefits in the treatment of active rheumatoid arthritis (RA).1,2 The objective of this analysis…
Abstract Number: 1524 • 2018 ACR/ARHP Annual Meeting
Malignancies and Serious Infections in Randomized Controlled Trials of Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Maria A. Lopez-Olivo¹, Jean Tayar², Natalia Zamora³, Gregory Pratt⁴ and Maria Suarez-Almazor⁵, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, ²Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX, ³Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁴Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ⁵Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX
Background/Purpose: Two JAK inhibitors are currently approved by different agencies worldwide for their use in patients with rheumatoid arthritis. The safety profile of these agents…
Abstract Number: 2551 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Treatment with Filgotinib: Week 132 Safety Data from a Phase 2b Open-Label Extension Study
Arthur Kavanaugh¹, Mark C. Genovese², Kevin Winthrop³, Maria Greenwald⁴, Lucia Ponce⁵, Favio Enriquez Sosa⁶, Mykola Stanislavchuk⁷, Minodora Mazur⁸, Alberto Spindler⁹, Regina Cseuz¹⁰, Natalya Nikulenkova¹¹, Maria Glowacka-Kulesz¹², Istvan Szombati¹³, Anna Dudek¹⁴, Neelufar Mozaffarian¹⁵, Joy Greer¹⁶, Rebecca Kunder¹⁵, Di An¹⁷, Luc Meuleners¹⁸, Robin Besuyen¹⁸, Rieke Alten¹⁹ and René Westhovens²⁰, ¹University of California, San Diego, School of Medicine, La Jolla, CA, ²Stanford University Medical Center, Palo Alto, CA, ³Oregon Health and Science University, Portland, OR, ⁴Desert Medical Advances, Palm Desert, CA, ⁵Cons. Priv. Temuco, Temuco, Chile, ⁶Clinstile SA de CV, Col., Mexico City, Mexico, ⁷Rheumatology, Vinnytsia Regional Clinical Hospital, Vinnytsia, Ukraine, ⁸IMSP Inst. de Cardiologie, Chisinau, Moldova, The Republic of, ⁹Centro Médico Privado de Reumatología, Centro Médico Privado de Reumatología, Argentina, ¹⁰Revita Reumatologiai Kft, Budapest, Hungary, ¹¹Vladimir Reg Clin Hosp, Vladimir, Russian Federation, ¹²Silesiana Centrum Medyczne, Wroclawska, Poland, ¹³Qualiclinic Kft., Budapest, Hungary, ¹⁴AMED Medical Center, Warsaw, Poland, ¹⁵Gilead Sciences, Inc., Foster City, CA, ¹⁶Gilead Sciences, Inc, Foster City, CA, ¹⁷Gilead Science, Inc., Foster City, CA, ¹⁸Galapagos NV, Mechelen, Belgium, Mechelen, Belgium, ¹⁹Schlosspark-Klinik University Medicine, Berlin, Germany, ²⁰Rheumatology, University Hospital KU Leuven, Leuven, Belgium
Background/Purpose: The orally administered, selective inhibitor of Janus Kinase 1 (JAK1), filgotinib (FIL), is currently being investigated for the treatment of rheumatoid arthritis (RA) in…
Abstract Number: 1525 • 2018 ACR/ARHP Annual Meeting
Effect of JAK-Inhibitor Versus Bdmards on Quality of Life in Rheumatoid Arthritis : A Meta Analysis of Randomized Controlled Trials
Mamadaly Boudhabhay¹, Thomas Barnetche² and Pascale Vergne-Salle³, ¹CHU de Limoges, Limoges, France, ²Rheumatology Department, FHU ACRONIM, Bordeaux University Hospital, Bordeaux, France, ³Rheumatology, CHU de Limoges, Limoges, France
Background/Purpose: Recent studies comparing JAK-inhibitors (Jak-i) and adalimumab seem to show a better efficacy of JAK-i on patient-reported outcomes in rheumatoid arthritis (RA). As there…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].